- Home
- TWST
as 12-24-2024 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.7B | IPO Year: | 2018 |
| Target Price: | $52.33 | AVG Volume (30 days): | 826.0K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.41 - $60.90 | Next Earning Date: | 01-31-2025 |
| Revenue: | $312,974,000 | Revenue Growth: | 27.69% |
| Revenue Growth (this year): | 21.67% | Revenue Growth (next year): | 17.52% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cho Dennis | TWST | See Remarks | Dec 16 '24 | Sell | $46.81 | 133 | $6,225.33 | 113,487 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Dec 6 '24 | Sell | $52.70 | 2,216 | $116,792.06 | 674,718 | |
| Green Paula | TWST | SVP of Human Resources | Dec 6 '24 | Sell | $52.70 | 860 | $45,325.44 | 133,715 | |
| Cho Dennis | TWST | See Remarks | Dec 6 '24 | Sell | $52.70 | 367 | $19,342.37 | 113,487 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Dec 6 '24 | Sell | $52.70 | 226 | $11,911.10 | 53,043 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Nov 25 '24 | Sell | $44.20 | 789 | $34,870.64 | 53,043 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Nov 11 '24 | Sell | $48.00 | 7,968 | $382,448.06 | 674,718 | |
| Green Paula | TWST | SVP of Human Resources | Nov 11 '24 | Sell | $48.00 | 1,347 | $64,653.31 | 133,715 | |
| Cho Dennis | TWST | See Remarks | Nov 11 '24 | Sell | $48.00 | 1,507 | $72,332.99 | 113,487 | |
| Finn Patrick John | TWST | President and COO | Nov 11 '24 | Sell | $48.00 | 10,340 | $496,299.32 | 221,061 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
Business Wire
7 days ago
Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
Zacks
10 days ago
Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MT Newswires
13 days ago
Wolfe Initiates Twist Bioscience at Outperform With $60 Price Target
Zacks
14 days ago
Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?
Insider Monkey
15 days ago
Why Twist Bioscience (TWST) Is the Worst ARK Stock to Buy According to Short Sellers
TipRanks
a month ago
Twist Bioscience named a Best Idea for 2025 at TD Cowen
Zacks
a month ago
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.